Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $95.00 | Equal Weight | Wells Fargo |
| 10/15/2024 | $96.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | $85.00 → $105.00 | Buy | Lake Street |
| 5/31/2024 | $100.00 | Buy | ROTH MKM |
| 4/26/2024 | $59.00 → $75.00 | Hold → Buy | Stifel |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/6/2023 | $70.00 | Outperform | Oppenheimer |
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, a
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. ("LeMaitre") (NASDAQ:LMAT) today announced the pricing of its offering of $150,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The issuance and sale of the notes is scheduled to settle on December 19, 2024, subject to customary closing conditions. LeMaitre also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first iss
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. ("LeMaitre") (NASDAQ:LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes. The notes
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, a
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and
Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and
Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00
Cantor Fitzgerald initiated coverage of Lemaitre Vascular with a rating of Neutral and set a new price target of $96.00
Lake Street resumed coverage of Lemaitre Vascular with a rating of Buy and set a new price target of $105.00 from $85.00 previously
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)